Crescita Therapeutics Q2 revenue $1,733Christian Fernsby ▼ | August 13, 2020
Crescita Therapeutics reported its financial results for the second quarter ended June 30, 2020.
Crescita Therapeutics Revenue was $1,733, a decrease of $7,629
Topics: Crescita Therapeutics
In Q2-F2019, the Company recognized $5,459 in up-front payments and guaranteed future minimum royalties in connection with the out-licensing agreement with Cantabria Labs.
Gross profit was $1,092, Operating expenses (excluding COGS) were $2,318, a decrease of $1,012.
Adjusted EBITDA1 was $(781), a decrease of $5,864, mainly due to the revenue recognized in connection with the Cantabria Agreement in Q2-F2019 of $5,459. ■